Day: October 15, 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13465-09-3,Indium(III) bromide,as a common compound, the synthetic route is as follows.

13465-09-3, Step C: Methyl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpyridin-2-yl)-3-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl)-2,2-dimethylpropanoate. InBr3 (228 mg, 0.643 mmol) was added to a 100 mL round-bottomed flask containing a solution of 7-((6-(((tert-butyldimethylsilyl)oxy)methyl)-5-methylpyridin-2-yl)chloromethyl)-3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine (1.0 g, 2.1 mmol), ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane (1.87 g, 10.7 mmol) and dichloromethane (30 mL) under N2. The resulting mixture was stirred at room temperature for 48 hours, then was poured into water (30 mL) and extracted with dichloromethane (30 mL*3). These extractions resulted in several organic solvent fractions which were combined, washed with brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated to dryness under reduced pressure. The material was purified by FCC (petroleum ether/ethyl acetate=1:0 to 3:1) to give the title compound (460 mg, 37% yield). MS (ESI): mass calcd. for C27H38F2N4O3Si 532.3; m/z found, 533.3 [M+H]+.

As the paragraph descriping shows that 13465-09-3 is playing an increasingly important role.

Reference£º
Patent; Janssen Pharmaceutica NV; Barbay, J. Kent; Chai, Wenying; Hirst, Gavin C.; Kreutter, Kevin D.; Kummer, David A.; McClure, Kelly J.; Nishimura, Rachel T.; Shih, Amy Y.; Venable, Jennifer D.; Venkatesan, Hariharan; Wei, Jianmei; (501 pag.)US2020/55874; (2020); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.119-91-5,2,2′-Biquinoline,as a common compound, the synthetic route is as follows.

Under argon atmosphere, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (66.0 mg, 0.114 mmol) was added to 4 mL of the solution of silver(I) tetrafluoroborate (22.2 mg, 0.114 mmol) in dichloromethane, and the mixture was stirred at room temperature for 15 minutes. Then, 2,2′-biquinoline (32.2 mg, 0.125 mmol) was added to the reaction solution, which was heated to reflux with stirring for one hour. The reaction solution was filtrated, and the filtrate was subjected to recrystallization by slow diffusion of dichloromethane-ether and dried to provide 103 mg of the complex of the yellow crystal. [Show Image] The NMR data of the obtained complex is provided below. 1H NMR (300 MHz, CDCl3) delta 8.79 (d, J = 8.7 Hz, 2H), 8.68 (d, J = 8.7 Hz, 2H), 7.92 (d, J = 8.2 Hz, 2H), 7.82 (d, J = 8.2 Hz, 2H), 7.73 (d, J = 6.8 Hz, 2H), 7.48 (t, J = 7.4 Hz, 2H), 7.28-7.23 (m, 6H), 7.13-7.06 (m, 10H), 7.02-6.96 (m, 8H), 6.54-6.50 (m, 2H), 1.85 (s, 6H); 31P NMR (122 MHz, CDCl3) delta -4.6 (d, J (31P-107Ag, 109Ag) = 361, 417Hz). The composition of the obtained complex was determined according to the same method as in Example 15. The present complex corresponds to the above composition formula (5)., 119-91-5

As the paragraph descriping shows that 119-91-5 is playing an increasingly important role.

Reference£º
Patent; Sumitomo Chemical Company, Limited; EP2360162; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

18511-72-3, 4,4-dinitro-2,2-Bipyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: 2,2′-bipyridine (0.025 g, 0.16 mmol) was dissolved in DCM:MeOH 2:1 (6 mL) and [Ir(pyba)2(Cl)]2 (0.100 g, 0.08 mmol) was added. The mixture was heated at reflux under nitrogen atmosphere,in the dark. After 6 h, the yellow solution was cooled to room temperature. The crude solid was purified by column on silicaeluted with MeCN:H2O:KNO3 7:1:0.5. The yellow fractionwas driedunder vacuum, redissolved in acetonitrile and filtered. The solutionwas dried again and the solidwas dissolved in a minimal amount ofmethanol and NH4PF6 (130 mg, 0.9 mmol) was added allowed tostir overnight. The solution was left in the fridge for two hours,recrystallised with ether and then filtered on sintered glass. Ayellow powder was collected by filtration. (42 mg, yield 30%), 18511-72-3

18511-72-3 4,4-dinitro-2,2-Bipyridine 11519563, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sinopoli, Alessandro; Wood, Christopher J.; Gibson, Elizabeth A.; Elliott, Paul I.P.; Dyes and Pigments; vol. 140; (2017); p. 269 – 277;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

115754-62-6, ((1,3-Dioxolan-2-yl)methyl)tributylphosphonium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a mixture of 8a (0.18g, 1.44mmol) and 1,3-dioxolan-2-ylmethyltributylphosphonium bromide (10) (0.28g, 0.75mmol) in dry DMF (3mL) a 0.48M solution of sodium ethoxide in ethanol (1.5mL, 0.73mmol) was added under argon atmosphere. The mixture was stirred at 90C for 22h and then water (75mL) was added. The aqueous phase was extracted with AcOEt (4¡Á50mL), and the resulting organic layer was washed with brine, dried over MgSO4, and evaporated. To a solution of the crude residue in THF (10mL), an aqueous solution of HCl 1N (40mL) was added and the mixture was stirred for 90min at room temperature. Then, water (50mL) was added and the aqueous phase was extracted with AcOEt (4¡Á50mL). The organic layer was dried over MgSO4 and evaporated. The crude product was purified by flash column chromatography (silicagel) using CH2Cl2/ hexane (9:1) as eluent, yielding 8b (0.14g, 0.34mmol, 72%) as a dark red solid. Found: C 73.55, H 3.90. C27H18O2S2 requires C 73.94, H 4.14%. Mp 220-222C. IR (KBr, cm-1): 1651 (C=O), 1600 (C=C), 1552 (C=C). 1H NMR (300MHz, CDCl3): delta 9.63 (d, J=7.7Hz, 1H, -CHO), 7.89-7.83 (m, 2H, phenyl-H), 7.81-7.75 (m, 2H, phenyl-H), 7.61 (d, J=15.3Hz, 1H, -CH=CH-CHO), 7.54-7.40 (m, 7H, phenyl-H+TT-H), 7.16 (d, J=2.1Hz, 1H, pyranylidene-H), 7.08 (br s, 1H, pyranylidene-H), 6.48 (s, 1H, TT-H), 6.47 (dd, J1=15.3 Hz, J2=7.7Hz, 1H, -CH=CH-CHO), 6.14 (s, 1H, pyranylidene=C-H). 13C NMR (100MHz, CDCl3): delta 192.5, 185.9, 154.2, 151.9, 148.7, 145.0, 139.5, 133.0, 132.8, 130.5, 129.9, 129.4, 128.8, 128.7, 125.7, 125.1, 125.0, 124.8, 124.6, 116.5, 108.5, 107.6, 102.7. HRMS (ESI+): found 439.0804 [M+H]+. C27H19O2S2 requires 439.0821., 115754-62-6

As the paragraph descriping shows that 115754-62-6 is playing an increasingly important role.

Reference£º
Article; Marco, A. Belen; Andreu, Raquel; Franco, Santiago; Garin, Javier; Orduna, Jesus; Villacampa, Belen; Alicante, Raquel; Tetrahedron; vol. 69; 19; (2013); p. 3919 – 3926;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4062-60-6,4062-60-6, N1,N2-Di-tert-butylethane-1,2-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A suspension of 30.1 mg (3-isobutyryl-6-methoxy-lH-indazol-l-yl)acetic acid in 1 mL DCM was treated with 38 muL oxalyl chloride and 10 muL DMF at room temperature for 2.5 hours. The reaction mixture was evaporated to dryness and the residue taken up in 1 mL dry DCM and treated with 8.6 mg N^-di-tert-butylethane-l^-diamine and 15 muL triethylamine over night. Purification of the reaction mixture on RP-etaPLC afforded the title compound following lyophilization. LC-MS: 4.19 min. (m/Z: 711.5, 689.5, 577.4, 633.5).

The synthetic route of 4062-60-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK & CO., INC.; WO2008/30390; (2008); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

2390-68-3, N-Decyl-N,N-dimethyldecan-1-aminium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Didecyldimethylammonium bromide (0.001 mol) was dissolved in 60 mL of distilled water by gentle heating and stirring. Potassium penicillin G (0.001 mol) was dissolved in 60 mL of distilled water by gentle heating and stirring. The two solutions were combined and the reaction mixture was heated and stirred for 30 minutes. The reaction mixture cooled to room temperature and then 60 mL of chloroform was added. The reaction mixture was stirred for an additional 30 minutes. The two phases were separated and the chloroform phase was washed several times with cool distilled water to remove any inorganic salt. The presence of chloride anions was monitored by silver nitrate test. A rotary evaporator removed the chloroform and an orange gel was obtained in 76% yield. 1H and 13C NMR (DMSO) were obtained. Melting point (hot plate apparatus)=25-30 C.

2390-68-3, 2390-68-3 N-Decyl-N,N-dimethyldecan-1-aminium bromide 16957, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Rogers, Robin D.; Daly, Daniel T.; Swatloski, Richard P.; Hough, Whitney L.; Davis, James Hilliard; Smiglak, Marcin; Pernak, Juliusz; Spear, Scott K.; US2007/93462; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135616-40-9,(R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine,as a common compound, the synthetic route is as follows.

5,46 g (0,01 mol) (R, R)-2, 2 – [1, 2-CYCLOHEXANDIYL) bis (nitrilomethylidyn)] bis [4,6-di- TERT.-BUTYL)-PHENOL] (Illa) werden in 50 ml Dichlormethan vorgelegt und mit 1,26 g (0,005 mol) VANADYLSULFAT-PENTAHYDRAT in 50 ml Dichlormethan versetzt. Nach 21 Stunden unter Rueckfluss wird das Loesungsmittel abdestilliert, und der Rueckstand per HPLC untersucht. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (11) : (LUI) =0% : 0% 100%.

135616-40-9, As the paragraph descriping shows that 135616-40-9 is playing an increasingly important role.

Reference£º
Patent; CLARIANT GMBH; WO2004/55028; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: (1R, 2R)-N-p-styrenesulfonyl-1,2-diphenylethylenediamine was synthesized as follows: 1g of (1R, 2R)-1,2-diphenylethylenediamine (4.71mmol) was dissolved in 20mL of CH2Cl2 in the presence of excessive of triethylamine and cooled to 0C, followed by the slow addition of 5mL of CH2Cl2 solution containing 1g of p-styrenesulfonyl chloride (4.78mmol), and stirred at room temperature overnight. The solution was washed with 5% NaOH aqueous solution, dried with MgSO4, and evaporated under vacuum to remove the solvent. The obtained solid was dissolved in diethyl ether, followed by the addition of 1mL of concentrated HCl (37wt%). The formed white precipitated was filtrated, treated with 5% NaOH aqueous, and then extracted with CH2Cl2 for 3 times. The combined organic phase was washed thoroughly with brine and dried over with MgSO4. The solvent was removed under vacuum and 1.28g of light yellow solid (72% yield) was obtained, which was denoted as V-TsDPEN [11]. 1H NMR (400MHz, DMSO-d6, 298K, TMS): delta6.64-7.38 (m, 14H), 6.64-6.67 (m, 1H), 5.87 (d, 1H, J=16.8Hz), 5.35 (d, 1H, J=11.2Hz), 4.33 (d, 1H, J=7.2Hz), 3.95 (d, 1H, J=6.6Hz) ppm., 29841-69-8

As the paragraph descriping shows that 29841-69-8 is playing an increasingly important role.

Reference£º
Article; Sun, Qi; Jin, Yinying; Zhu, Longfeng; Wang, Liang; Meng, Xiangju; Xiao, Feng-Shou; Nano Today; vol. 8; 4; (2013); p. 342 – 350;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29176-55-4, 2,9-Dichloro-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Preparation of E-l-(6-methyl-pyridin-2-yl)-ethanone-O-r3-(9-chloro-rif101phenanthrolin- 2-yl)-prop-2-ynyl1-oxime2,9-Dichloro-[l,10]phenanthroline (0.46 g) and E-l-(6-methyl-pyridin-2-yl)-ethanone-0- prop-2-ynyl-oxime (382 mg) were dissolved in THF (5 ml_). Diisopropylamine (1.88 g), dichlorobis (triphenylphospine)palladium(II) (57 mg) and copper(I) iodide (58 mg) were added. After stirring for 3h at 55C the reaction mixture was poured into water, extracted with ethyl acetate and washed with brine. The organic phase was dried over sodium sulfate, concentrated and purified by chromatography over silica to give l-(6-Methyl-pyridin-2-yl ethanone-O-[3-(9-chloro-[l,10]phenanthrolin-2-yl)-prop-2-ynyl]-oxime as a brown solid., 29176-55-4

The synthetic route of 29176-55-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SYNGENTA PARTICIPATIONS AG; TRAH, Stephan; ZAMBACH, Werner; STIERLI, Daniel; NEBEL, Kurt; BORTOLATO, Andrea; WO2012/62844; (2012); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

(2)1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tri-tert-butyl (8.3 mg)In DMF (0.1 mL) and DIEA (10 [mu] L)A solution of HBTU (5.5 mg) in DMF (100 muL) was added, (N1) (4.6 mg) in DMF (200 muL) and DIEA (20 muL)And the mixture was stirred at room temperature for 1.5 hours. Water (100 muL) was added,Purification by preparative HPLC gave (N 2) (3.5 mg).

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; Fujifilm RI Pharma Co., Ltd.; Hirofumi, Fukunaga; Do En, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Chou, Rumpf; (131 pag.)JP2016/183151; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI